Pharvaris PHVS
NASDAQ PHVS
$35.25 -0.41 (-1.15%)
As of: Sep 4, 2026 · 3:59 PM EDT

Pharvaris (PHVS) Free Cash Flow (2020 - 2026)

Pharvaris' (PHVS) quarterly Free Cash Flow came in at -$57.0 million in Q1 2026, down 41.52% YoY from -$97.5 million in Q1 2025, and down 29.1% on a QoQ basis from -$44.2 million in Q4 2025.

Analysis

Pharvaris (PHVS) Free Cash Flow (2020 - 2026) Analysis & Trends

Pharvaris (PHVS) has 7 years of Free Cash Flow data on file, last reported at -$57.0 million in Q1 2026.

  • Quarterly Free Cash Flow fell 41.52% year-over-year to -$57.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$171.0 million (down 19.21% YoY) and the FY2025 annual result came in at -$154.7 million, down 19.5% from the prior year.
  • Free Cash Flow fell to -$57.0 million in Q1 2026, from -$44.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $49676.0 billion in Q3 2023 to a low of -$49691.2 billion in Q2 2023.
  • A 5-year average of -$926.4 million and a median of -$29.8 million in 2024 frame the typical range for Free Cash Flow.
  • The widest YoY moves for Free Cash Flow: up 325629580.06% in 2023, down 340811256.1% in 2023.
  • Tracing PHVS's Free Cash Flow over 5 years: stood at -$20.8 million in 2022, then dropped by 23.0% to -$25.6 million in 2023, then sank by 45.31% to -$37.2 million in 2024, then retreated by 18.82% to -$44.2 million in 2025, then decreased by 29.1% to -$57.0 million in 2026.
  • The last three Free Cash Flow figures came in at -$57.0 million (Q1 2026), -$44.2 million (Q4 2025), and -$35.8 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Free Cash Flow (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.01 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 572.80 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -563.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -389.61 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 437.80 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 292.04 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 477.44 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -95.09 Mn
10 Pharvaris 2.10 Bn 1.73 Bn 85,072.10 -43.91 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -43.91 Mn
Mar 31, 2026 -57.03 Mn
Dec 31, 2025 -44.18 Mn
Sep 30, 2025 -35.83 Mn
Jun 30, 2025 -33.96 Mn
Mar 31, 2025 -40.30 Mn
Dec 31, 2024 -37.18 Mn
Sep 30, 2024 56,936.14 Bn
Jun 30, 2024 -55,830.28 Bn
Mar 31, 2024 -26.29 Mn
Dec 31, 2023 -25.59 Mn
Sep 30, 2023 49,675.96 Bn
Jun 30, 2023 -49,691.24 Bn
Mar 31, 2023 -27.03 Mn
Dec 31, 2022 -20.80 Mn
Sep 30, 2022 31,779.58 Bn
Jun 30, 2022 -33,632.36 Bn
Mar 31, 2022 -20.04 Mn
Dec 31, 2021 -14.22 Mn
Sep 30, 2021 -11.80 Mn